Bimekizumab efficacy through one year in patients with moderate to severe plaque psoriasis in subgroups defined by prior biologic treatment: Pooled results from four phase 3/3b trials . (2022). SKIN The Journal of Cutaneous Medicine, 6(6), s64. https://doi.org/10.25251/skin.6.supp.64